OKYO Pharma Ltd

OKYO Pharma Ltd has logged zero cyber incidents and zero material red-flag 8-K filings over the past 90 days, indicating operational stability in the near term. However, a compressed observation window can miss structural risks—dilution from financing rounds, equity raises, and financing history often surface in broader review periods. The full $49 Report extends analysis to 12 months, quantifies dilution risk with a proprietary score, maps 8-K context and officer movements, and flags AI-detected risk signals across SEC filings and management disclosures. The full $49 Report adds 12-month event history, dilution risk scoring, financing trajectory analysis, and AI risk flagging across core SEC documents.